Summary
This 8-K filing from Eli Lilly & Co. on November 19, 2009, primarily announces a significant leadership change within its science and technology division. Dr. Steven M. Paul, Executive Vice President of Science and Technology, is set to retire on February 28, 2010. This transition involves a substantial severance package for Dr. Paul, including a $2 million cash payment and enhanced pension benefits due to 10 additional years of service credit for pension calculation purposes. Dr. Paul will be succeeded by Dr. Jan Lundberg, who currently holds the position of Executive Vice President of Discovery Research at AstraZeneca. This appointment signals a strategic move for Lilly, potentially bringing in new expertise and direction in scientific innovation. Investors should monitor how this leadership transition impacts the company's research and development pipeline and future growth prospects.
Key Highlights
- 1Dr. Steven M. Paul, EVP of Science and Technology, to retire effective February 28, 2010.
- 2Dr. Paul to receive a cash severance payment of $2,000,000.
- 3Dr. Paul will receive 10 years of additional service credit for pension benefit calculation.
- 4Dr. Paul will be eligible for a full, unreduced pension benefit.
- 5Dr. Jan Lundberg, currently EVP of Discovery Research at AstraZeneca, will succeed Dr. Paul.
- 6This leadership change is effective as of the announcement date, with Dr. Paul's retirement scheduled for early 2010.